CIDRAP newsletters options
Investigators with the United Kingdom's RECOVERY trial reported yesterday that a preliminary analysis of data from the azithromycin arm of the trial showed the antibiotic had no impact on clinical outcomes in hospitalized COVID-19 patients.
Vaccine arrived at 145 centers today, and 425 sites will get deliveries tomorrow.
A large UK epidemiologic study finds no association with GBS, which has been a concern.
Other regions considering further measures include London, Germany, Italy, and the Netherlands.
Political affiliation appears to have more impact than local disease spread in 2 new studies.
Data published late last week in the Centers for Disease Control and Prevention's (CDC's) Morbidity and Mortality Weekly Report (MMWR) detailed public school costs for recommended COVID-19 mitigation strategies, which averaged $442 per student but varied widely.
The step allows health workers to begin giving the vaccine and offers guidance on immunization policy.
Emergency approval makes the vaccine available and offers hope for altering the course of the pandemic.
One study points to the use of certain medications, and the other shows elevated risk in non-white populations.
Pressure over emergency use approval raises worries that the process has been rushed.
Studies show a 57% higher COVID-19 hospital rate for gynecologic cancer and a 29% higher rate for all cancers in black patients.
In patients needing noninvasive breathing support, those who got the 2-drug combo recovered in 10 days, compared with 18 days for remdesivir alone.
A large body of data shows the high-dose vaccine yields greater protection than standard-dose vaccines.
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
Originally published by CIDRAP News Dec 10
Though flu activity in the United States remains well below expected levels for this time of year, the Centers for Disease Control and Prevention (CDC) today reported the first pediatric flu death of the 2020-21 season, a child who died from influenza B.
A study published yesterday in Science by researchers in Massachusetts suggests that a coronavirus outbreak linked to an international biotech conference in Boston in February is linked to more than 300,000 national and international infections with SARS-CoV-2, the virus that causes COVID-19.
FDA Commissioner Stephen Hahn has said the FDA will make its approval decision shortly after today's meeting.
Distribution challenges include local logistics, equitable reach, special populations, and cold storage.
The 3,124 new deaths—a single-day record—surpass the death tolls from the 9/11 and Pearl Harbor attacks.
The campaign focuses on avoiding enclosed spaces with people not in your "pod."
